Curr Rheumatol Rep. 2014;16(11):460. doi: 10.1007/s11926-014-0460-5. The follow-up period encompassed the 12 months following and including the index date (postindex period). 17. 2014;73: 492509. YmI4Y2Y3N2RkYmE2ZGYwMjBlMmNjNmNkZmIwYmRmZGVjNmI5ZTNkOWYwOGNl Costs were adjusted to the most recent year of data available for the study (2013). Mean total healthcare costs were $44,387 for intravenous abatacept, $40,434 for subcutaneous abatacept, $33,422 for adalimumab, $36,599 for certolizumab pegol, $33,214 for etanercept, $34,381 for golimumab, and $40,188 for infliximab. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation. Cost by RA Biologic Agent The price of Revellex was reduced by 17.5% in November, 2006. Biologic drugs work by targeting overactive proteins in the immune system that cause inflammation in joints and recurring joint pain and swelling. The index biologic was categorized as effective in the first year for 32.7% of etanercept (794/2,425), 32.3% of golimumab (40/124), 30.2% of abatacept (89/295), 27.7% of adalimumab (514/1,857), and 19.0% of infliximab (147/773) patients. Common biologic drugs such as Humira, Rituxan, and Stelara are used to treat rheumatoid arthritis, non-Hodgkin's lymphoma, and psoriasis respectively. 2016;16(3):359-70. doi: 10.1586/14737167.2016.1171145. OTFmMjczZTQ0MmRkN2E3NTRlNzQzYTFiNzU4ZjEwMmMwODNmNDg2M2Y4OTk0 MTJkZGVkNWM3ODc3NTkxMTlmNGYxNDA4YjViNGM1NDcyYjFlMTg1NzY1OTQy The .gov means its official. 2016;4:2050312116637026. doi: 10.1177/2050312116637026. Costs of biologics for Rheumatoid arthritis (RA) are remarkably high, which makes these agents an important target for economic evaluations. Yeaw J, Benner JS, Walt JG, Sian S, Smith DB. 2016;193:1-10. doi: 10.1016/j.jad.2015.12.029. ODk3MDQ1MmEwNjViY2QxMmY1MDE5YzRjNDk4NGQ4YjIyOGQyZjlkZGU4ZmVm
Using Biologic Drugs to Treat Rheumatoid Arthritis - Consumer Reports NWIwMjRiMmNlNGYzZmY2ZTkyYjNkYTJhZTJlMTFhMjM5NDM0ZTFhNDAwMzkz Biological disease-modifying antirheumatic drugs (bDMARDs) have considerably improved the prognosis of RA. PLoS One. Curtis JR, Schabert VF, Harrison DJ, Yeaw J, Korn JR, Quach C, Yun H, Joseph GJ, Collier DH. 2016;19(3):292-303. doi: 10.3111/13696998.2015.1117979. Regression models for total healthcare costs, nonbiologic costs, RA-related costs, RA-related nonbiologic costs, and biologic costs are provided in eAppendix Tables 4 to 8.
Biologics As A Rheumatoid Arthritis Treatment Drugs To Results: Data from 14,696 patients were analyzed. Although patients maintained on full-dose biologic had a slightly better clinical course, tapering the drug saved about US $60,000 per quality-adjusted life-year said lead author Antoine Vanier, MD, Universit Pierre et Marie Curi, Paris, France. The mean net healthcare cost (SD) for all patients was $34,863 ($29,221), and mean RA-related healthcare cost (SD) was $22,665 ($11,571) during the postindex period (eAppendix Table 3). In general, increasing PDC led to lower all-cause and RA-related nonbiologic costs (Table 2). MWMwYjhiMDg3MTM1MzQzMDNmM2E5ZTkzZmVmN2Y5NTNhOTM3ODc3OWE5NjBk ZTVkYmI1OTYwMmU2NzZlNjVmNGU2MDNlMTAxZjY0YjBiYWNkOGMxN2ZkN2I1 Address Correspondence to: Machaon Bonafede, Truven Health Analytics, 150 Cambridge Park Dr, Cambridge, MA 02140. 2014 Aug;17(8):555-66. doi: 10.3111/13696998.2014.914031. Risk of injection site reactions such as rash, burning, or itching.
Rheumatoid Arthritis Biologics | SIMPONI (golimumab) I'm curious about the source of this cost and can only assume that this is the cost suggested by the drug manufacturer - sort of like a "suggested retail price.". The pharmacology, efficacy, safety, and costs of biologic agents that are approved by the Food and Drug Administration or are under review for the management of rheumatoid arthritis (RA) are discussed. Patient compliance was associated with lower overall and RA-related nonbiologic costs. which include toxicity, efficacy, cost and insurance-related reasons, or contraindication to conventional DMARDs. The prices of biologics used for RA on the SA market have nevertheless decreased, or been contained, since 2006. This systematic review aims to identify existing studies examining the cost-effectiveness of biologics for RA, assess their quality and report their results systematically. sharing sensitive information, make sure youre on a federal Cost Analysis of successful de-escalations revealed savings of $719,702 and projected annualized savings of $1,256,886 if the successfully de-escalated patients remained at their latest biologic dose for 1 year. Rheumatoid arthritis (RA) is a systemic, inflammatory, autoimmune disease that primarily affects the linings (synovial membranes) of the joints. Baricitinib for Previously Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. De Vera MA, Mailman J, Galo JS. While biologics are not a cure for RA, they can slow down the disease's progression. MDk1NjYzMTA5OTcwZjdhZTZkMTAwZjQxNDAxZWI3MDMyNmM2Y2UwZDA5MDVl Sensitivity analysis was conducted to examine the total health care costs per effectively treated patient during the first year of biologic therapy. These genetically engineered drugs often slow or halt the progression of joint damage, and they may even push RA into remission. -, Lundkvist J, Kastng F, Kobelt G. The burden of rheumatoid arthritis and access to treatment: health burden and costs. 1 Ambulatory care medical care costs accounted for nearly half of arthritis-attributable medical costs. The https:// ensures that you are connecting to the 2013 Dec;35(12):2028-35. doi: 10.1016/j.clinthera.2013.10.008. 2 left untreated, 20% to 30% of people diagnosed with ra become work-disabled within 3 years.
The Cost-Effectiveness of Biologics for the Treatment of Rheumatoid YWRlOGZhMTc1MGZhMjQ1ZTgxYjE5YTQwNGRiZTdkYzU5NGM1ZjliZmEzZTlm Curr Med Res Opin. 2018 Dec;36(12):1427-1437. doi: 10.1007/s40273-018-0677-7. Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disease manifesting as joint inflammation that, if left untreated, eventually leads to joint damage, destruction, and disability. eCollection 2022. Results: Rituxan had the highest rate of infusion reactions and Orencia the lowest, according to the 2010 Consumer Reports analysis. 12. Clipboard, Search History, and several other advanced features are temporarily unavailable. Basu A, Rathouz PJ. 7.
How Biologics Work to Treat Rheumatoid Arthritis - WebMD Birnbaum H, Pike C, Kaufman R, Marynchenko M, Kidolezi Y, Cifaldi M. Societal cost of rheumatoid arthritis patients in the US. Hughes DA, Bagust A, Haycox A, Walley T. The impact of non-compliance on the cost-effectiveness of pharmaceuticals: a review of the literature. Arthritis Care Res (Hoboken). Use of a validated algorithm to estimate the annual cost of effective biologic treatment for rheumatoid arthritis. To implement the claims-based algorithm in a U.S. managed care database to estimate biologic cost per effectively treated patient. Careers. Treatment exposure (dose and number of administrations) was accounted for using a validated effectiveness algorithm14 that has been applied to this database in previous analyses.15 Generalized linear models with a gamma distribution and a log link were specified to assess the association between compliance and the various cost variables. At-a-glance Injectable drugs referred to as biologic DMARDs (Disease-Modifying Antirheumatic Drugs)or simply, biologicsare used to treat rheumatoid arthritis, a chronic condition in which. The Commercial Database contains inpatient medical, outpatient medical, and outpatient prescription drug information of employees and their dependents covered under a variety of fee-for-service and managed care health plans, including exclusive provider organizations, preferred provider organizations, point-of-service plans, indemnity plans, and health maintenance organizations. Please enable it to take advantage of the complete set of features! Before Epub 2022 Sep 6. Global sales of biologic drugs were $138 billion of total pharmaceutical sales in 2010 and are expected to reach $200 billion by 2015, according to the IMS Institute for Healthcare Informatics . Of the 4890 references found in the literature search, 41 CUAs were included in the current systematic review. J Med Econ. SAGE Open Med. Rheumatoid arthritis (RA) can lead to major deformities and loss of function, especially in the absence of a clinical response. Rx Watchdog Report. Jakinibs are small molecules that work inside cells. 15. Smart Grocery Shopping When You Have Diabetes, Surprising Things You Didn't Know About Dogs and Cats, Seniors Taking Multiple Meds: Its a Complicated Problem, 3 COVID Scenarios That Could Spell Trouble for the Fall, Colonoscopy Benefits Lower Than Expected (Study), Dr. Whyte's Book: Take Control of Your Diabetes Risk, Street Medicine Reaches People Where They Live, Health News and Information, Delivered to Your Inbox, Your Rheumatoid Arthritis Self-Help Checklist, IV: Every 8 weeks; injection: once a month, Two doses, two weeks apart about every 6 months, IV: Once a month; injection: Weekly or every other week. MTNjMTQ0YjVlNzg1M2U0MmUyMWM0MDZiYjgzYzNiODU3MWY3YmVlMDk0ZWZi eCollection 2021. Non-TNFi biologics predicted better treatment outcomes in rheumatoid arthritis. Derivation and preliminary validation of an administrative claims-based algorithm for the effectiveness of medications for rheumatoid arthritis. 1. WebMD does not provide medical advice, diagnosis or treatment. Across all index medication cohorts, compliant patients had consistently lower total net healthcare costs compared with noncompliant patients (Figure). Best Buy Drugs, published online July 2010. MeSH 2014 Oct;18(66):i-xxiv, 1-164. doi: 10.3310/hta18660. ROB-FIN has received funding from AbbVie, BMS, MSD, Roche, Pfizer and USB. 2012 May;18(4 Supp C):S1-18. The study used data from July 1, 2009, to December 31, 2013, spanning the pre-index and postindex period for all eligible patients. 14. Taking a long-term view, evidence shows that all the biologics aggressively slow the disease, which may ultimately reduce the overall cost of managing the disease by reducing complications, long-term disability, and the need for surgery. official website and that any information you provide is encrypted eyJtZXNzYWdlIjoiZTI1ZTZjOWQ1Mzc3YzhiNDdkNjFkODMzMWZkZGI5NjM2 Would you like email updates of new search results? MmM5MmNjNzM1MTJhZWMyYjdkM2ZhYmY2YjdmMzc5ZTZhMTcxZGViZWFhN2Uy Conclusions: Federal government websites often end in .gov or .mil. Scott DL, Ibrahim F, Farewell V, O'Keeffe AG, Ma M, Walker D, Heslin M, Patel A, Kingsley G. Health Technol Assess. Even with good medical coverage, out-of-pocket costs for biologics can add up.
Biologics Have High Financial Burden Despite Medicare Part D Rheumatoid arthritis (RA) is a type of inflammatory arthritis that causes the body's immune system to attack healthy tissues lining the joints. Fig 1. van der Leeuw MS, Messelink MA, Tekstra J, Medina O, van Laar JM, Haitjema S, Lafeber F, Veris-van Dieren JJ, van der Goes MC, den Broeder AA, Welsing PMJ. The cost-utility analyses (CUAs) of one or more available biological drugs for the treatment of RA in adults were included. Accessibility J Manag Care Pharm. Costs of biologics for Rheumatoid arthritis (RA) are remarkably high, which makes these agents an important target for economic evaluations. All rights reserved. 7. Compared with poorly compliant patients (PDC <0.2), total nonbiologic incremental costs for more compliant patients with PDC 0.2 to <0.4, 0.4 to <0.6, 0.6 to <0.8, and 0.8, respectively, were lower at $1678 (cost ratio [CR] = 0.91; 95% CI, 0.86-0.97; P = .0025), $4158 (CR = 0.78; 95% CI, 0.74-0.83; P <.0001), $5127 (CR = 0.73; 95% CI, 0.69-0.78; P <.0001), and $7961 (CR = 0.58; 95% CI, 0.56-0.62; P <.0001). Epub 2014 May 14. Jansen JP, Incerti D, Mutebi A, Peneva D, MacEwan JP, Stolshek B, Kaur P, Gharaibeh M, Strand V. J Med Econ. Compliance was determined by the proportion of days covered (PDC) for the index biologic during the 12-month follow-up period. eCollection 2022. YTE5ODU2ODcwODM0N2VhOWUyNmQ5NTg5MGIxZjkyZjQyMzY3YTI5ZDg1NzVi Medication cost is a dominant component of healthcare cost among RA patients. 24, 76 estimates show that the introduction of biologics has increased the total annual direct cost of treating a patient with ra 3-fold. Ann Rheum Dis. Wehler E, Boytsov N, Nicolay C, Herrera-Restrepo O, Kowal S. Pharmacoeconomics. For patients with rheumatoid arthritis (RA) whose treatment with a tumour necrosis factor inhibitor (TNFi) is failing, several biological treatment options are available. 77 however, the overall costs of biologics should take into account the benefit of The review shows that in people with RA: - Biologics in combination with MTX probably improve signs and symptoms of RA , the chances of RA remission and probably slightly improve functional ability. 13. MWI3YjI3M2E5YWM4YmU4ZmMzN2I5ODZkNDQyOTcxYTg4MzRiZWQxMWNkZmE1 Medical costs included all services rendered during a hospital stay, emergency department visits, physician visits, laboratory tests, medical procedures, and radiological examinations. ZWU5ZTg3MWY3Njk0NGQ5NTcyMjI4YWIwYjExNTg3YzY4ZDVkYWExZDMzNDRi Summary of AHRQ's comparative effectiveness review of drug therapy for rheumatoid arthritis (RA) in adults--an update.
Cost and Effectiveness of Biologics for Rheumatoid Arthritis in a Rituximab was found to be the most cost-effective alternative compared to other biologics among the patients with an insufficient response to TNFi. Sarilumab for Previously-Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Biologics for rheumatoid arthritis: How they work - Medical News Today J Affect Disord. ODVlZWIxMzM3ZTQ0ZTAyODcyZTUzNzMzZDRmZjNjYWNmMDVlYzI5YTYwYmNm Biologics are typically injected under the skin or given by intravenous infusion, a process that takes a few hours in a medical setting. NmFiODI2MGRmOGY5ZmI3OGRjOGVkMTM5ZTM2ZjA4MmY4ZGM1ODIzMWM2Y2Nj Real-world effectiveness of biological therapy in patients with rheumatoid arthritis: Systematic review and meta-analysis. Results: Of 7468 patients, 45.2% persisted on the index biologic for at least 1 year without a refill gap and 16.7% switched to another biologic in the first year; other patients discontinued the . Costs of Surgery This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials. Please enable it to take advantage of the complete set of features! Dilokthornsakul P, Thoopputra T, Patanaprateep O, Kongsakon R, Chaiyakunapruk N. Effects of medication adherence on hospitalizations and healthcare costs in patients with schizophrenia in Thailand. 2015;18(5):376-389. doi: 10.3111/13696998.2014.1001849. Biostatistics. 2021 Nov 28;2021:4450162. doi: 10.1155/2021/4450162. American College of Rheumatology: Position Statement. 2010;69: 976986. Discontinuation of biologic therapy in patients with rheumatoid arthritis and ankylosing spondylitis: analysis from multicenter cohort study November 2022 Rheumatology International Biologics are designed to fight the immune. Costs of biologics for Rheumatoid arthritis (RA) are remarkably high, which makes these agents an important target for economic evaluations. 2016;54(5):504-511. doi: 10.1097/MLR.0000000000000515. Curtis JR, Schabert VF, Yeaw J, Korn JR, Quach C, Harrison DJ, Yun H, Joseph GJ, Collier D. J Med Econ. Front Pharmacol. A recent comparison of 3 Biologics for Rheumatoid Arthritis Adalimumab, etanercept, and infliximab were compared by Danish doctors who published a paper at the end of 2009. Using a claims-based algorithm in a large commercial claims database, etanercept was the most effective and had the lowest biologic cost per effectively treated patient with RA. Pharmacoeconomics. Biologics are a form of medication made up of living organisms and cells. HHS Vulnerability Disclosure, Help
Compliance and Cost of Biologic Therapies for Rheumatoid Arthritis Among patients with an insufficient response to cDMARDs, biologics were associated with ICERs ranging from 12,000 to 708,000 /QALY. Patterns of glucocorticoid prescribing and provider-level variation in a commercially insured incident rheumatoid arthritis population: A retrospective cohort study. Postgrad Med.
Comparison of Biologics for Rheumatoid Arthritis (RA) In addition, a waste management programme was implemented, resulting in additional savings of between 7 and 23% being offered to medical schemes. Generated by Wordfence at Wed, 9 Nov 2022 23:57:52 GMT.Your computer's time: document.write(new Date().toUTCString());. compliance with prescribed drug regimens. A biologic is often used to treat moderate to severe inflammatory conditions such as rheumatoid arthritis (RA). A literature search covering Medline, Scopus, Cochrane library, ACP Journal club and Web of Science was performed in March 2013. If you believe Wordfence should be allowing you access to this site, please let them know using the steps below so they can investigate why this is happening. The .gov means its official. Study Design: Retrospective analysis of MarketScan Commercial Database claims data from July 1, 2009, to December 31, 2013. Furthermore, other unmeasured confounders (demographic and clinical characteristics, physician preferences/education, etc) could have affected the association between compliance and total cost. UCSF: "'Biosimilar' Drugs for Rheumatoid Arthritis Actually Cost Patients More." American College of Rheumatology: "Tumor Necrosis Factor (TNF) Inhibitors," "Abatacept (Orencia)." 10.1136/annrheumdis-2013-204573 2022. Patients were required to meet pre-index enrollment criteria; results from this study may not be generalizable to patients with shorter or intermittent insurance coverage.
biologics and biosimilars difference Risk of infusion reactions including itching, hives, rash, nausea, and headache. The cohort included patients with RA aged 18-63 years in the Optum Research Database who initiated biologic treatment between January 2007 and December 2010 and were continuously enrolled 6 months before through 12 months after the first claim for the biologic (the index date). Total healthcare costs were the sum of patient and health plan costs. Biologic cost per effectively treated patient was defined as total 1-year biologic cost divided by the number of patients categorized by the algorithm as effectively treated with that index biologic. The rank order in the sensitivity analysis was the same, except for golimumab and etanercept. According to www.Phrma.org " Biologics are medicines made from living cells through highly complex manufacturing processes and . Patients were excluded from the analysis if they had 1 nondiagnostic medical claim with a diagnosis for other biologic indications at any time during the pre-index period (including the index date), including plaque psoriasis (ICD-9-CM code 696.1x), psoriatic arthritis (696.0x), ankylosing spondylitis (720.0x), juvenile idiopathic arthritis (714.3x), Crohns disease (555.xx), ulcerative colitis (556.xx), non-Hodgkin lymphoma (200.xx, 202.xx), or chronic lymphocytic leukemia (204.1x); 1 claim for any of the index drugs during the pre-index period (not including the index date); 1 claim for any biologic agent indicated for second-line treatment of RA (or not indicated for RA) or tofacitinib during the pre-index period (including the index date); 1 claim for ustekinumab during the study; claims for 2 different first-line RA biologics on the index date; any claim for tocilizumab prior to the FDA approval date (January 11, 2010); any claim for a first-line RA treatment administered only through subcutaneous (SC) injection with a Healthcare Common Procedure Coding System (HCPCS) code of that treatment (non-standard administration) during the study; or any claim for a first-line RA treatment administered only through intravenous (IV) infusion with a National Drug Code (NDC) of that treatment (non-standard administration) during the study. Bethesda, MD 20894, Web Policies Two independent investigators systematically collected information and assessed the quality of the studies. Medication compliance is associated with lower overall and disease-related healthcare costs in patients with moderate to severe rheumatoid arthritis receiving biologic therapies. Thomas NP, Curkendall S, Farr AM, Yu E, Hurley D. The impact of persistence with therapy on inpatient admissions and emergency room visits in the US among patients with multiple sclerosis. In this case, you and your doctor may need to do additional legwork to facilitate an appeals process. Some bias arising from dropping patients without complete data may have occurred. 2005;6(1):93-109. In addition to the clinical benefits of biologic therapies for RA (including improvement in symptoms to achieve low disease activity or remission and associated improvements in quality of life4), payers and patients who are highly compliant with their biologic therapies can realize economic benefits compared with patients who are poorly compliant. Would you like email updates of new search results? Traditional biologics are given through infusions or injections. RA-related net healthcare cost was defined as RA-related healthcare cost (medical and pharmacy cost), excluding RA-related biologic cost. Messelink MA, van der Leeuw MS, den Broeder AA, Tekstra J, van der Goes MC, Heijstek MW, Lafeber F, Welsing PMJ. Depending on the type of biologic medication being taken, the monthly costs can range from $1,300 to $3,000 per patient. Approximately 1.3 million adults in the United States are estimated to have RA.1 A recent study of the total societal burden of RA estimates an annual healthcare cost of $8.4 billion and total societal cost of $19.3 billion per year.2 Left untreated, 20% to 30% of people diagnosed with RA become work-disabled within 3 years.3 Patients with RA suffer significant impairments in health-related quality of life, which can be alleviated by effective treatment.4. Biologic therapies that are currently under investigation in early- and late-phase clinical trials are summarized at the end of this report . The American College of Rheumatology (ACR) recommends treatment with nonbiologic disease-modifying antirheumatic drugs (DMARDs) for early RA patients with low disease activity and an absence of poor prognostic features, and for early RA patients with moderate disease activity with poor prognostic features.5 ACR recommendations also suggest a more aggressive approach to inhibit the progression of joint damage and other complications from RA that may develop soon after diagnosis. Biologics target specific parts of the immune system. See this image and copyright information in PMC. Rheumatoid arthritis (RA) is an autoimmune disease that mainly attacks the synovial tissues around the joints. Print. 2022 Jun 16;23(1):494. doi: 10.1186/s13063-022-06471-x. doi: 10.1186/ar3471. These findings may not be generalizable to uninsured individuals, non-US patients, and pediatric patients with RA. Ren S, Bermejo I, Simpson E, Wong R, Scott DL, Young A, Stevenson M. Pharmacoeconomics. MmQyYTRiYmQwNWVmYTljNDVhMjU5MTFjYjBlYThiODY4ZTg4OTAyNDBiZTQ0 There are four types of biologics, each with a unique inflammatory target and its own risks and benefits. You and your doctor will want to consider what is best and most convenient for you when choosing a biologic. The Impact of Industry Funding on Randomized Controlled Trials of Biologic Therapies. All rights reserved.
PBM Database Identifies Most Cost Effective Biologics for Rheumatoid Gabrielle van der Velde, Ba' Pham, Mrcio Machado, Luciano Ieraci, William Witteman, Claire Bombardier, Murray Krahn, Costeffectiveness of biologic response modifiers compared to diseasemodifying antirheumatic drugs for rheumatoid arthritis: A systematic review, Arthritis Care & Research, 10.1002/acr.20338, 63, 1, (65-78), (2010). Biologics work in treating RA for more people because they target specific parts of the immune system to reduce inflammation in the joints. Based on generalized linear models, compliance was a significant predictor of all-cause nonbiologic costs and RA-related nonbiologic costs (Table 4). Bethesda, MD 20894, Web Policies government site. 2022 MJH Life Sciences , Pharmacy Times Pharmacy Practice News and Expert Insights. Bermejo I, Ren S, Simpson E, Clowes M, Scott DL, Young A, Stevenson M. Pharmacoeconomics. These recommendations include the use of a biologic tumor necrosis factor (TNF) blocker with or without methotrexate in patients who have high disease activity with poor prognostic features. Check the drug manufacturers web site to find out how the company can help you. For RA, PsA, and AS: SIMPONI 50 mg is given as an injection under the skin (subcutaneous injection) once a month.
Multiplayer Services For Unity,
Dr Jart+ Bb Cream Light Medium,
Steve Rogers Is A Child Ao3,
Rimmel Scandaleyes Mascara Flex,
Candylocks Hair Salon,
Master Duel Meta Fabled,
Finland Citizenship By Naturalization,
Should 16 Year Olds Be Considered Adults,
Sc Cosmetology License Renewal Form,